AIMS AND BACKGROUND: Undifferentiated carcinoma of the parotid gland is a poor-prognosis lesion. Results in unresectable lesions, treated with radiotherapy alone, are very disappointing. METHODS: Six patients with T3-4 N0-1 inoperable lesions were treated with conventional radiotherapy (64-70 Gy, 2 Gy per fraction 5 times a week) and concomitant cisplatin (100 mg/m2, days 1, 22 and 43). Four weeks after radiotherapy, adjuvant chemotherapy (cisplatin, 80 mg/m2, day 1, + VP16, 100 mg/m2, days 1, 3 and 5, q = 3 weeks, for 3 cycles) was given. RESULTS: A median dose of 66 Gy (range, 64-70 Gy) was delivered, and all patients received 3 courses of cisplatin during radiotherapy. Five of 6 patients received all three chemotherapeutic adjuvant courses. Two months after the end of treatment, 3 CR (50%), 2 PR (33%) and 1 NC (16%) was observed. Median CR and PR duration was 26+ and 10 months, respectively. Median overall survival was 18 months. No severe acute or late toxicity was observed. CONCLUSIONS: Concomitant chemoradiotherapy followed by adjuvant chemotherapy in advanced unresectable undifferentiated parotid carcinoma is feasibile and well tolerated. The high percentage of long-lasting CR is encouraging.
AIMS AND BACKGROUND: Undifferentiated carcinoma of the parotid gland is a poor-prognosis lesion. Results in unresectable lesions, treated with radiotherapy alone, are very disappointing. METHODS: Six patients with T3-4 N0-1 inoperable lesions were treated with conventional radiotherapy (64-70 Gy, 2 Gy per fraction 5 times a week) and concomitant cisplatin (100 mg/m2, days 1, 22 and 43). Four weeks after radiotherapy, adjuvant chemotherapy (cisplatin, 80 mg/m2, day 1, + VP16, 100 mg/m2, days 1, 3 and 5, q = 3 weeks, for 3 cycles) was given. RESULTS: A median dose of 66 Gy (range, 64-70 Gy) was delivered, and all patients received 3 courses of cisplatin during radiotherapy. Five of 6 patients received all three chemotherapeutic adjuvant courses. Two months after the end of treatment, 3 CR (50%), 2 PR (33%) and 1 NC (16%) was observed. Median CR and PR duration was 26+ and 10 months, respectively. Median overall survival was 18 months. No severe acute or late toxicity was observed. CONCLUSIONS: Concomitant chemoradiotherapy followed by adjuvant chemotherapy in advanced unresectable undifferentiated parotid carcinoma is feasibile and well tolerated. The high percentage of long-lasting CR is encouraging.
Authors: Aaron W Pederson; Joseph K Salama; Daniel J Haraf; Mary Ellen Witt; Kerstin M Stenson; Louis Portugal; Tanguy Seiwert; Victoria M Villaflor; Ezra E W Cohen; Everett E Vokes; Elizabeth A Blair Journal: Head Neck Oncol Date: 2011-07-26
Authors: Brian J Gebhardt; James P Ohr; Robert L Ferris; Umamaheswar Duvvuri; Seungwon Kim; Jonas T Johnson; Dwight E Heron; David A Clump Journal: Am J Clin Oncol Date: 2018-09 Impact factor: 2.339
Authors: Alexandra D Jensen; Anna V Nikoghosyan; Karen Lossner; Klaus K Herfarth; Jürgen Debus; Marc W Münter Journal: BMC Cancer Date: 2012-05-02 Impact factor: 4.430
Authors: Sati Akbaba; Dina Ahmed; Andreas Mock; Thomas Held; Suzan Bahadir; Kristin Lang; Mustafa Syed; Juliane Hoerner-Rieber; Tobias Forster; Philippe Federspil; Klaus Herfarth; Peter Plinkert; Juergen Debus; Sebastian Adeberg Journal: Cancers (Basel) Date: 2019-11-01 Impact factor: 6.639
Authors: Sati Akbaba; Tilman Bostel; Kristin Lang; Suzan Bahadir; Djoeri Lipman; Heinz Schmidberger; Christoph Matthias; Nicole Rotter; Andreas Knopf; Christian Freudlsperger; Peter Plinkert; Juergen Debus; Sebastian Adeberg Journal: Front Oncol Date: 2020-11-11 Impact factor: 6.244